RT info:eu-repo/semantics/article
T1 No differences between men and women in adverse drug reactions related to psychotropic drugs: a survey from France, Italy and Spain
A1 D'Incau, Paola
A1 Lapeyre-Mestre, Maryse
A1 Carvajal García-Pando, Alfonso
A1 Donati, Monia
A1 Salado Valdivieso, María Inés
A1 Rodríguez, Lauriane
A1 Sáinz Gil, María
A1 Escudero, Antonio
A1 Conforti, Anita
K1 Psicofármacos
AB A large number of studies have suggested that being a woman represents a potential risk factor for the development of adverse drug reactions (ADRs). The aim of this study is to further explore the differences between men and women with regard to reported ADRs, particularly those associated with psychotropic drugs. We used spontaneous reports of suspected ADRs collected by Midi-Pyrénées (France), Veneto (Italy) and Castilla y León (Spain) Regional Pharmacovigilance Centres (January 2007-December 2009). All the reports including a psychotropic medication were selected in a first step; age distribution, seriousness and type of ADRs were compared between men and women. Reports of nonpsychotropic drugs were similarly identified and treated. The absolute number of reports and the proportion, considering population, were higher in women than in men. This was observed for all reports, but was particularly higher for psychotropic drugs (592 vs. 375; P < 0.001) than for nonpsychotropics drugs (5193 vs. 4035; P < 0.001). Antidepressants were the most reported (women, 303; men, 141; P < 0.001); the reporting rates (number of reports divided by exposed patients in the same period, estimated through sales data) for these drugs, however, were not significantly different between women (0.87 cases per 10 000 treated persons per year) and men (0.81 cases per 10 000 treated persons per year). Although there was a higher number of reports of ADRs in women, ADR reporting rates might be similar as highlighted by the case of antidepressants. Antidepressant ADRs in fact were similarly reported in men and in women. Gender differences are sometimes subtle and difficult to explore. International networks, as the one established for this study, do contribute to better analyse problems associated with medications.
PB 0767-3981
YR 2014
FD 2014
LK http://uvadoc.uva.es/handle/10324/9048
UL http://uvadoc.uva.es/handle/10324/9048
LA eng
NO Fundam Clin Pharmacol. 2014 Jun;28(3):342-8
NO Producción Científica
DS UVaDOC
RD 19-abr-2024